Karl-Heinz Krause

About

Karl-Heinz Krause is full professor at the Department of Pathology and Immunology, Geneva Medical Faculty. He is a trained specialist in internal medicine and infectious diseases and has a joint appointment with the Geneva University Hospitals. His research is centered around molecular mechanisms and therapy of age-related diseases. His main fields of research are reactive oxygen species (ROS)-generating NADPH oxidases, as well as pluripotent stem cell-derived neurons. For both topics, his research team puts a particular focus on physiology and pathologies of the central nervous system. Of particular importance among his stem cell research activities is the development of engineered neural tissues. Karl-Heinz Krause has also been active in the biotechnology field. He is coinventor on numerous patents. He is also cofounder of several start-up companies, including GENKYOTOX (development of NADPH oxidase inhibitors), Neurix (pluripotent stem cell-derived neural tissues, Transcure bioservices (stem cell-based humanized mouse models), Antion Biosciences (therapeutic minigenes and HIV cure), and HPlus therapeutics (development of proton channel inhibitors).

Employment

• University of Geneva, Faculty of Medicine full professor
  2001 - Present
• Hôpitaux Universitaires de Genève Professor Adjoint
  1998 - 2001
• Hôpitaux Universitaires de Genève Maître d'enseignement et de recherche
  1992 - 1998
• Hôpitaux Universitaire de Geneve Chef de clinique scientifique
  1989 - 1992
• Hopitaux Universitaire de Genève Fellow
  1987 - 1989
• Hopitaux Universitaire de Genève Assistant physician
  1984 - 1987
• Ludwig-Maximilians-Universität München Assistant physician
  1982 - 1984

Education

• University of Geneva Privat-Docent
  1993 - Present
• Ludwig-Maximilians-Universitat Munchen Lehrstuhl Stoffwechselbiochemie Thesis in medicine
  1982 - 1984

Projects & Funding

Projects & funding information is unavailable.

Publications (44)

• Redox Mechanisms Driving Skin Fibroblast-to-Myofibroblast Differentiation
  Antioxidants 2025 DOI: 10.3390/antiox14040486
  +Save
• Adipose-Derived Stromal Cells Exposed to RGD Motifs Enter an Angiogenic Stage Regulating Endothelial Cells
  International Journal of Molecular Sciences 2025 DOI: 10.3390/ijms26030867
  +Save
• Generation of Individualized, Standardized, and Electrically Synchronized Human Midbrain Organoids
  Cells 2025 DOI: 10.3390/cells14151211
  +Save
• Adipose-Derived Stromal Cells within a Gelatin Matrix Acquire Enhanced Regenerative and Angiogenic Properties: A Pre-Clinical Study for Application to Chronic Wounds
  Biomedicines 2023 DOI: 10.3390/biomedicines11030987
  +Save
• Cancer Spheroids and Organoids as Novel Tools for Research and Therapy: State of the Art and Challenges to Guide Precision Medicine
  Cells 2023 DOI: 10.3390/cells12071001
  +Save
• Decreased Levels of SARS-CoV-2 Fusion-Inhibitory Antibodies in the Serum of Aged COVID-19 Patients
  Diagnostics 2022 DOI: 10.3390/diagnostics12081813
  +Save
• Optimization of Thymidine Kinase-Based Safety Switch for Neural Cell Therapy
  Cells 2022 DOI: 10.3390/cells11030502
  +Save
• Transcriptomic Analysis of E. coli after Exposure to a Sublethal Concentration of Hydrogen Peroxide Revealed a Coordinated Up-Regulation of the Cysteine Biosynthesis Pathway
  Antioxidants 2022 DOI: 10.3390/antiox11040655
  +Save
• Alpha-1 Antitrypsin Reduces Disease Progression in a Mouse Model of Charcot-Marie-Tooth Type 1A: A Role for Decreased Inflammation and ADAM-17 Inhibition
  International Journal of Molecular Sciences 2022 DOI: 10.3390/ijms23137405
  +Save
• A Cellular Assay for Spike/ACE2 Fusion: Quantification of Fusion-Inhibitory Antibodies after COVID-19 and Vaccination
  Viruses 2022 DOI: 10.3390/v14102118
  +Save